In conclusion, albeit at preliminary stages, our data support the use of these novel EphA2-targeting drug conjugates suggesting that they may provide an exciting new strategy for pancreatic cancer drug development. The gene discussed is EPHA2; the disease is familial pancreatic carcinoma.